Developing Drugs to Treat (Diseases of) Aging

  • September/October 2007
  • By C.H Westphal, M.A Dipp, L. Guarente, D.A. Sinclair

Pasteur or Ponce de León?

   

C. H. Westphal MD, PhD1; M. A. Dipp, MD, PhD1; L. Guarente PhD2; D. A. Sinclair PhD3

1 Sirtris Pharmaceuticals
2 MIT
3 Harvard Medical School and Glenn Institute of Aging

Abstract
For thousands of years, society has been seeking a means to extend healthy life span. Yet the key genes that dictate life span were discovered only within the last decade. The challenge now is to utilize these discoveries to develop drugs to treat broadly prevalent diseases of aging, such as type 2 diabetes and cancer. From this perspective, we discuss the promising drug targets identified thus far in the field of aging research. Some of these targets appear to underlie the beneficial effects of calorie restriction, the most robust means to extend healthy life span in mammals. Insights gained from human clinical trials of calorie restriction, and from therapeutic interventions in animal models of diseases of aging, delineate a potential development path for drugs that treat diseases of aging.

 

To read the entire article you must log in:

Most of our content — all daily news, blogs, and videos — is free. Magazine stories are paid. To read this story, you must have a subscription or you must use a reading credit. Registration to Technology Review is free and entitles registrants to three free reading credits.

Username or REGISTER
Password  
   
 
Advertisement

MAGAZINE

Can We Build Tomorrow's Breakthroughs?

Manufacturing in the United States is in trouble. That's bad news not just for the country's economy but for the future of innovation.

Videos

Meet 2011 TR35 Winner Jesse Robbins

More

Advertisement

Technology Review Lists

TR50

Our list of the 50 most innovative companies, including the following:

Apple

Amyris

Siemens

Akamai

More

Advertisement
Advertisement